Power3 Medical Products, Inc. (PWRM.OB)

Power3 Medical is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.

Breast cancer occurs when cells in the breast tissue divide and grow without control. The cell cycle is the natural mechanism that regulates the growth and death of cells. When the normal cell regulators malfunction and cells do not die at the proper rate, there is a failure of cell death (apoptosis) therefore cell growth goes unchecked. As a result, cancer begins to develop as cells divide without control, accumulating into a mass of extra tissue called a tumor. A tumor can be either non-cancerous (benign) or cancerous (malignant). As a tumor grows, it elicits new blood vessel growth from the surrounding normal healthy tissues and diverts blood supply and nutrients away from this tissue to feed itself. This process is termed "angiogenesis"- the development (genesis) of new blood vessels (angio). Unregulated tumor angiogenesis facilitates the growth of cancer throughout the body.

Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the Power3 Medical Products' patient database. Statistical analysis by linear discriminates function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

For more information, please visit the website: http://www.power3medical.com

******************************

Nature's Sunshine Products Inc. (Nasdaq:NATR) announced the appointment of Gregory L. Probert, an executive with extensive direct selling experience, as well as marketing and operational experience in consumer-oriented businesses, as a member of the Board of Directors, to serve as a Class II director. Nature's Sunshine also named Mr. Probert Executive Vice Chairman.

Nature's Sunshine Products, Inc., together with its subsidiaries, engages in the manufacture and marketing of nutritional and personal care products worldwide.

*********************************

Blue Gold Beverages, Inc. (BGBV)

Drinking water has the following benefits:

Look Younger with Healthier Skin: You'll look younger when your skin is properly hydrated. Water helps to replenish skin tissues, moisturizes skin and increase skin elasticity.

Better Productivity at Work: Your brain is mostly made up of water, thus drinking water helps you think better, be more alert and more concentrate.

Blue Gold Beverages, Inc. (BGBV) is pleased to announce its wholly owned subsidiary EPIC Nutrition, Inc. has signed an exclusive distribution agreement with Contemporary Marketing, Inc. ("CMI") one of the leading National Sales and Marketing companies in the USA. The agreement provides for CMI to be the exclusive broker for EPIC's NRG™, Goodnight™ and COLDsense™ brands for key retailers Walgreens, CVS, Target, GNC and Stop & Shop resulting in thousands of potential points of distribution at these retail outlets.

CMI will spearhead the new product launches of EPIC's new NRG Pro-N-Go™, a nationally branded energy shot infused with 25g of bioavailable protein and Goodnight™, a proprietary 2.5 fl oz shot targeted at the rapidly expanding $521m US sleep and relaxation category (Zenith International 1/20/11) and COLDsense™, a natural cold and flu remedy into the $2.6b US Cold/Allergy/Sinus tablet market (SymphonyIRI Group, Inc 9/5/10).

Blue Gold Beverages, Inc. is a leading high end producer of private label water and specialty beverages in North America. Some of our products include all natural sodas, teas, non-alcoholic wine coolers and energy drinks. Blue Gold Beverages head office situated in Montreal, Quebec, Canada, we use 3rd party bottling plants strategically located across North America depending on the geographical location of our clients. With the recent acquisition of TY Recycling, Blue Gold Beverages has entered into the polymer recycling business, selling PET and Nylon waste. This is in-line with the company's strategy of becoming environmentally responsible by eliminating its carbon footprint, and increasing shareholder value.

For more information BGBV, please visit: http://www.bluegoldbeverages.com

***************************

First Capital Inc. (Nasdaq:FCAP) the Board of Directors of First Capital, Inc. (Nasdaq:FCAP) has declared a quarterly cash dividend of $0.19 (nineteen cents) per share of common stock, according to William W. Harrod, President and Chief Executive Officer. The dividend will be paid on June 30, 2011 to shareholders of record as of June 16, 2011.

First Capital, Inc. operates as the bank holding company for First Harrison Bank that provides various banking services to individuals and business customers.

*********************************

AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) announced that it has closed its previously announced underwritten public offering of common stock. The total number of shares sold was 6,352,119, comprised of 5,750,000 shares of common stock initially offered and an additional 602,119 shares of common stock sold pursuant to the underwriters' exercise of their over-allotment option. Net proceeds are approximately $104.3 million, after deducting underwriting discounts and commissions and transactional fees, at a price of $17.50 per share to the public. J.P. Morgan Securities LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering, with Canaccord Genuity Inc. acting as co-lead manager.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received seven thousand five hundred dollars ($7,500) in cash from a third party (9186 2780 Quebec Inc) for 1 week of media advertisement services for Blue Gold Beverages, Inc. (BGBV).